Maternal Omega-3 Supplementation to Reduce Bronchopulmonary Dysplasia — MOBYDIck  

Child Development Clinical Trial

Official title: Maternal Omega-3 Supplementation to Reduce BronchopulmonarY Dysplasia in Very Preterm Infants (MOBYDIck Trial)

Status Active, not recruiting

Clinical Trial Summary

The aim of this randomized controlled trial is to determine whether docosahexaenoic acid (or DHA, an omega-3 lipid) supplementation in lactating mothers providing breast-milk to their infant born below 29 0/7 weeks of gestational age (GA) improves BPD-free survival at 36 weeks post-menstrual age (PMA). Half of participants will receive docosahexaenoic acid (DHA), an omega-3 lipid, while the other half will receive a placebo.

Clinical Trial Description

Every year in Canada, 1500 babies who are born early (prematurely) develop a serious lung disease called bronchopulmonary dysplasia (BPD). BPD causes major health problems in these infants, especially in their early childhood. In most situations, breast-milk is the ideal source of nutrition for growth and development of premature babies. However, diets of Canadian mothers are generally deficient in omega-3 lipids (essential fats), resulting in lower protection from these omega-3 lipids in mother's milk-fed infants. Previous research has shown that giving DHA to mothers of premature babies is safe both for the mother and for their baby, and is an efficient way of helping babies meet their dietary requirements from breast-milk. Furthermore, this previous research also suggests that this intervention may reduce the risk of BPD in premature babies receiving breast-milk. ;

Related Conditions & MeSH terms

• Bronchopulmonary Dysplasia
• Child Development
• Neonatal and Perinatal Conditions

• NCT number: NCT02371460
• Study type: Interventional
• Source: CHU de Quebec-Universite Laval
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: June 23, 2015
• Completion date: March 2025